CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CELZ evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $6.3M
- Lead Asset:
- celz-100 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CELZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CELZ
Creative Medical Technology Holdings, Inc. (CELZ) is a clinical-stage biotechnology company developing regenerative medicine therapies based on proprietary allogeneic stem cell and hypoimmune iPSC platforms, with lead programs in chronic lower back pain and Type 1 Diabetes.
Key risk: Pre-revenue stage
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$6.3M
Cash Runway
—
Lead Asset
celz-100 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..
Similar companies
Creative Medical Technology Holdings, Inc. (CELZ) is a clinical-stage biotechnology company developing regenerative medicine therapies based on proprietary allogeneic stem cell and hypoimmune iPSC platforms, with lead programs in chronic lower back pain and Type 1 Diabetes.
- Completed enrollment in the FDA-cleared ADAPT Phase 1/2 trial for CELZ-201-Olastrocel for chronic lower back pain as of December 2025 [news].
- Reported cash of $0.0M revenue and net income of -$1.5M for the period ending June 30, 2026, with shareholders' equity of $8.7M [sec].
- Received FDA Fast Track designation for the ADAPT trial in August 2025 [sec_mda · as of 2026-08-07].
- Secured FDA authorization for expanded access therapy using CELZ-201 for managing abnormal glucose tolerance and preventing Type 1 Diabetes in high-risk individuals in March 2024 [sec · filed 2026-07-24].
- Initiated a biodefense platform combining AI with iPSC technology to develop countermeasures for toxic environmental exposures [sec · filed 2026-07-24].
What works
- Lead ADAPT trial for chronic lower back pain completed enrollment and received FDA Fast Track designation, with interim data showing no serious adverse events and improvements in disability and pain [sec_mda · as of 2026-08-07].
- Proprietary AlloStem™ clinical cell line (CELZ-200) with Master Cell Bank and Drug Master File provides a platform for multiple programs including Type 1 Diabetes and immunotherapy [sec · filed 2026-06-26].
- Partnership with Greenstone Biosciences integrates AI-driven drug discovery and multi-gene editing to enhance hypoimmune iPSC lines [sec · filed 2026-07-24].
- DSMB review of first five patients in CELZ-201 trial concluded the trial may proceed as planned, supporting safety profile [sec · filed 2026-07-24].
What to weigh
- No revenue reported as of June 30, 2026, with a net loss of $1.5M, indicating the company is pre-commercialization and dependent on funding [sec].
- Shareholders' equity of $8.7M as of June 30, 2026, is relatively modest for a clinical-stage biotech with multiple programs [sec].
- The ADAPT trial expansion to include patients on opioids adds complexity and may delay final data readout [sec_mda · as of 2026-08-07].
- The biodefense platform and AI initiatives are early-stage and have not yet produced clinical data [sec · filed 2026-07-24].
From the filings
Quoted directly from source documents.
Completed enrollment in ADAPT trial for CELZ-201-Olastrocel
“Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point”
News · December 17, 2025
DSMB review of first five patients concluded trial may proceed
“The DSMB reviewed safety data from the first five dosed patients concluding that the trial may proceed as planned, underscoring the safety profile of CELZ-201”
SEC filings · July 24, 2026
FDA Fast Track designation for ADAPT trial
“This randomized Phase 1/2 study received FDA Fast Track designation in August 2025.”
SEC MD&A · August 7, 2026
Risks & what to watch (4)›
Key risks
- Pre-revenue stage — No revenue reported as of June 30, 2026, with ongoing net losses, requiring continued funding to sustain operations [sec].
- Modest equity base — Shareholders' equity of $8.7M as of June 30, 2026, may limit runway for multiple clinical programs [sec].
- Clinical trial expansion — ADAPT trial expansion to include opioid-using patients adds regulatory and operational complexity [sec_mda · as of 2026-08-07].
- Early-stage platform — Biodefense and AI initiatives are exploratory with no clinical data yet [sec · filed 2026-07-24].
What to watch
- Completion of enrollment in the expanded ADAPT cohort and subsequent data readouts [sec_mda · as of 2026-08-07].
- Progress of the CELZ-201 CREATE-1 Type 1 Diabetes program following FDA IND clearance [sec · filed 2026-06-26].
- Updates from the Greenstone partnership on AI-driven iPSC development and multi-gene editing [sec · filed 2026-07-24].
- Any new financing or partnership announcements given the pre-revenue status [sec].
Sources: News · SEC filings · SEC MD&A · Generated September 28, 2026 · How we verify sources →
Run CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.08
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$199K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 38,290 | $79K |
| vanguard capital management llc | 20,350 | $42K |
| xtx topco ltd | 14,260 | $29K |
| susquehanna international group, llp | 10,469 | $22K |
| vanguard fiduciary trust co | 5,518 | $11K |
| wells fargo & company/mn | 5,000 | $10K |
| tower research capital llc (trc) | 2,092 | $4K |
| morgan stanley | 534 | $1K |
| fmr llc | 250 | $515 |
| sbi securities co., ltd. | 1 | $2 |
Showing top 10 of 11 institutional holders of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.3%
- Days to cover
- 2.5
- Shares short
- 156,760
- Daily short volume (May 21, 2026)
- 41.7%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CELZ short interestGovernance
Frequently asked questions
What is the AI investment thesis for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.?
Creative Medical Technology Holdings, Inc. (CELZ) is a clinical-stage biotechnology company developing regenerative medicine therapies based on proprietary allogeneic stem cell and hypoimmune iPSC platforms, with lead programs in chronic lower back pain and Type 1 Diabetes.
What is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s lead drug candidate?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s most advanced tracked candidate is celz-100 (Preclinical) for Chronic Back Pain; Chronic Low-back Pain.
Who is the CEO of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.?
Mr. Timothy Warbington is the chief executive officer of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ).
Where is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. headquartered?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) is headquartered in Phoenix, AZ, United States.
What therapeutic areas does CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. focus on?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. develops therapies across Metabolic, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.